Cortechs.ai’s collaboration with the Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET) marks a major advancement in the use of artificial intelligence for neurodegenerative disease care. At the heart of this initiative is NeuroQuant® for ARIA, an AI-powered imaging platform that provides automated, quantitative analysis of brain lesions associated with amyloid-related imaging abnormalities (ARIA). The technology is clinically validated for both 2D and 3D FLAIR as well as T2GRE and SWI sequences, making it the only platform that can reliably detect and measure cerebral microbleeds and superficial siderosis in Alzheimer's patients undergoing anti-amyloid therapy.

NeuroQuant® for ARIA will be deployed across ALZ-NET’s nationwide network, enabling physicians to monitor ARIA-related changes with greater accuracy and speed. By offering discounted access to this tool, Cortechs.ai supports broader adoption in a range of clinical environments. This partnership empowers clinicians with real-time, AI-enhanced insights, facilitating earlier detection of potential complications and more informed decisions regarding treatment safety. Importantly, the tool helps streamline workflows and ensures consistency in monitoring across diverse imaging sites and protocols.

By combining NeuroQuant®’s imaging precision with ALZ-NET’s expansive real-world data infrastructure, this collaboration aims to improve safety surveillance, inform future treatment guidelines, and ultimately enhance patient care. It exemplifies how AI and data integration can reshape how Alzheimer’s disease is monitored and managed in clinical practice. With growing adoption of anti-amyloid therapies, the ability to safely track treatment impact is critical—and this partnership offers a scalable, evidence-based path forward for clinicians and researchers alike.

MedTech Spectrum's Summary

AI-Powered Imaging Innovation:Cortechs.ai’s NeuroQuant® for ARIA is the first clinically validated AI tool to detect and quantify ARIA-related brain lesions, offering precise monitoring of cerebral microbleeds, edema, and superficial siderosis in Alzheimer's patients on anti-amyloid therapies.

Improved Clinical Decision-Making:The platform enables early, accurate detection of imaging abnormalities, helping physicians make safer, more informed treatment decisions and reduce risks associated with anti-amyloid immunotherapies.

Scalable, Real-World Impact:Through integration with ALZ-NET’s nationwide clinical data network, the collaboration supports large-scale data collection to shape future treatment guidelines and improve long-term Alzheimer’s care outcomes.